Becton dickinson to pay $175 million for misleading investors about alaris infusion pump

Washington, d.c.--(newsfile corp. - december 16, 2024) - the securities and exchange commission today announced settled charges against becton, dickinson and company, a new jersey-based medical device manufacturer known as bd, for repeatedly misleading investors about risks associated with its continued sales of its alaris infusion pump and for overstating its income by failing to record the costs of fixing multiple software flaws with the pump.
BDX Ratings Summary
BDX Quant Ranking